Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy

Sponsor

Virion Therapeutics (Industry)

Overall Status

Recruiting

CT.gov ID

NCT06070051

Collaborator

(none)

Enrollment

Locations

Arms

15.9

Anticipated Duration (Months)

Patients Per Site

1.5

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This Phase 1b clinical study is a multi-center, open-label, dose escalation, prime only, and prime plus boost therapeutic vaccination study of 2 distinct chimpanzee adenoviral vectors (AdC6 and AdC7), containing parts of hepatitis B virus (HBV) core and polymerase antigens fused within glycoprotein D in a cohort of chronic hepatitis B (CHB)-infected adult participants who are currently receiving entecavir, tenofovir (tenofovir alafenamide fumarate or tenofovir disoproxil fumarate), or lamivudine, with documented HBV viral load suppression for at least 12 months.

Approximately 24 participants will be enrolled in Group 1 and randomized to Cohort 1a or Cohort 1b. Those assigned to Cohort 1a will receive a low dose prime therapeutic vaccination of vector AdC7 on Day 1, followed by a booster vaccination on Day 91 using vector AdC6. Those assigned to Cohort 1b will receive a low dose prime therapeutic vaccination of vector AdC6 on Day 1, and will not receive a booster vaccination.

Group 2 will then enroll approximately 24 participants randomized to Cohort 2a or Cohort 2b. Those assigned to Cohort 2a will receive a high dose prime therapeutic vaccination of vector AdC7 on Day 1, followed by a booster vaccination on Day 91 using vector AdC6. Those assigned to Cohort 2b will receive a high dose prime therapeutic vaccination of vector AdC6 on Day 1, and will not receive a booster vaccination.

All vaccine doses will be administered by intramuscular (IM) injection.

All study participants will be followed for a total of 1 year post-prime vaccination.

Condition or Disease	Intervention/Treatment	Phase
Chronic Hepatitis B	Biological: VRON-0200-AdC6 Biological: VRON-0200-AdC7	Phase 1

Study Design

Study Type:

Interventional

Anticipated Enrollment :

48 participants

Allocation:

Randomized

Intervention Model:

Sequential Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase 1b Multi-Center, Open-Label, Dose-Escalation, Prime And Boost Vaccination Evaluation of VRON-0200 Using Two Chimpanzee Adenoviral Vectors in Adult Participants With Chronic HBV Infection Who Are Currently Receiving HBV Nucleos(t)Ide Reverse Transcriptase Inhibitors

Actual Study Start Date :

Sep 26, 2023

Anticipated Primary Completion Date :

Jul 23, 2024

Anticipated Study Completion Date :

Jan 23, 2025

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Cohort 1a: Low Dose VRON-0200-AdC7 Prime, VRON-0200-AdC6 Boost Participants assigned to Cohort 1a will receive a low dose prime vaccination of AdC7 vector on Day 1. They will receive a low dose boost vaccination of vector AdC6 on Day 91.	Biological: VRON-0200-AdC6 VRON-0200 chimpanzee adenovirus serotype 6 vaccine vector Biological: VRON-0200-AdC7 VRON-0200 chimpanzee adenovirus serotype 7 vaccine vector
Experimental: Cohort 1b: Low Dose VRON-0200-AdC6 Prime, No Boost Participants assigned to Cohort 1b will receive a low dose prime vaccination of AdC6 vector on Day 1. They will not receive a booster vaccination.	Biological: VRON-0200-AdC6 VRON-0200 chimpanzee adenovirus serotype 6 vaccine vector
Experimental: Cohort 2a: High Dose VRON-0200-AdC7 Prime, VRON-0200-AdC6 Boost Participants assigned to Cohort 2a will receive a high dose prime vaccination of AdC7 vector on Day 1. They will receive a high dose boost vaccination of AdC6 vector on Day 91.	Biological: VRON-0200-AdC6 VRON-0200 chimpanzee adenovirus serotype 6 vaccine vector Biological: VRON-0200-AdC7 VRON-0200 chimpanzee adenovirus serotype 7 vaccine vector
Experimental: Cohort 2b: High Dose VRON-0200-AdC6 Prime, No Boost Participants assigned to Cohort 2b will receive a high dose prime vaccination of AdC6 vector on Day 1. They will not receive a booster vaccination.	Biological: VRON-0200-AdC6 VRON-0200 chimpanzee adenovirus serotype 6 vaccine vector

Outcome Measures

Primary Outcome Measures

Treatment Emergent Adverse Events [28 days]
Number and percent of participants with 1 or more treatment-emergent adverse events within 28 days after each therapeutic vaccine dose by cohort.
Grade 3 Adverse Events [28 days]
Number and percent of participants with Grade 3 or higher local and/or systemic reactions within 28 days after each therapeutic vaccine dose by cohort.
Clinically Significant Changes in Lab Values [28 days]
Number and percent of participants with clinically significant changes from pre-vaccination laboratory values within 28 days after each therapeutic vaccine dose by cohort.
Serious Adverse Events [6 months]
Number and percent of participants with serious adverse events within 6 months after each therapeutic vaccine dose by cohort.
Medically Attended Adverse Events [6 months]
Number and percent of participants with medically attended adverse events within 6 months after each therapeutic vaccine dose by cohort.

Secondary Outcome Measures

Adverse Events [360 days]
Number and percentage of adverse events for all participants through Day 360.
T Cell Frequencies [360 days]
Change from baseline in vaccine-induced CD8+ T cell frequencies in the blood.

Other Outcome Measures

Hepatitis B Virus DNA [360 days]
Quantitative changes from baseline over time in HBV DNA
Hepatitis B Virus Pregenomic RNA [360 days]
Quantitative changes from baseline over time in HBV pgRNA
Hepatitis B Surface Antigen [360 days]
Quantitative changes from baseline over time in HBsAg

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 55 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Documented chronic HBV infection (eg, HBsAg+ ≥ 6 months with detectable HBsAg at screening)
Receipt of either entecavir, tenofovir (tenofovir alafenamide fumarate or tenofovir disoproxil fumarate), or lamivudine for at least 12 months before screening with no reported antiviral resistance during this time; still on treatment at screening and expected to stay on therapy during the study period
Virally suppressed for > 12 months (HBV DNA < 40 IU/mL)
No clinical diagnosis of advanced liver fibrosis and/or cirrhosis

Exclusion Criteria:

History of hepatic decompensation, advanced fibrosis, or liver transplantation
History of hepatocellular carcinoma
History of risk factors for thrombosis and thrombocytopenia
Documented hepatitis A, hepatitis C, hepatitis D, hepatitis E, or HIV (or history of prior active disease)
Pregnant, nursing, or planning a pregnancy during the trial